- Home
- SPXX vs ALDX Comparison
SPXX vs ALDX Comparison
Compare SPXX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXX
- ALDX
- Stock Information
- Founded
- SPXX 2004
- ALDX 2004
- Country
- SPXX United States
- ALDX United States
- Employees
- SPXX N/A
- ALDX N/A
- Industry
- SPXX Trusts Except Educational Religious and Charitable
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- SPXX Finance
- ALDX Health Care
- Exchange
- SPXX Nasdaq
- ALDX Nasdaq
- Market Cap
- SPXX 329.9M
- ALDX 304.9M
- IPO Year
- SPXX N/A
- ALDX 2014
- Fundamental
- Price
- SPXX $17.35
- ALDX $6.55
- Analyst Decision
- SPXX
- ALDX Strong Buy
- Analyst Count
- SPXX 0
- ALDX 2
- Target Price
- SPXX N/A
- ALDX $10.00
- AVG Volume (30 Days)
- SPXX 51.3K
- ALDX 729.0K
- Earning Date
- SPXX 01-01-0001
- ALDX 05-01-2025
- Dividend Yield
- SPXX 7.55%
- ALDX N/A
- EPS Growth
- SPXX N/A
- ALDX N/A
- EPS
- SPXX N/A
- ALDX N/A
- Revenue
- SPXX N/A
- ALDX N/A
- Revenue This Year
- SPXX N/A
- ALDX N/A
- Revenue Next Year
- SPXX N/A
- ALDX N/A
- P/E Ratio
- SPXX N/A
- ALDX N/A
- Revenue Growth
- SPXX N/A
- ALDX N/A
- 52 Week Low
- SPXX $13.57
- ALDX $2.85
- 52 Week High
- SPXX $16.05
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- SPXX 42.07
- ALDX 54.11
- Support Level
- SPXX $16.83
- ALDX $6.22
- Resistance Level
- SPXX $17.09
- ALDX $6.87
- Average True Range (ATR)
- SPXX 0.27
- ALDX 0.44
- MACD
- SPXX -0.03
- ALDX -0.03
- Stochastic Oscillator
- SPXX 39.51
- ALDX 56.30
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.